Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$20.29 USD

20.29
4,247,997

+0.72 (3.68%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $20.22 -0.07 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights Griffon, HNI, ADMA Biologics and First Bank

Griffon, HNI, ADMA Biologics and First Bank have been highlighted in this Screen of The Week article.

J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer

The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.

Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Moumita C. Chattopadhyay headshot

4 Stocks With Increasing Cash Flows to Enrich Your Portfolio

Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health. Hence, GFF, HNI, ADMA and FRBA are worth buying.

Wall Street Analysts Believe Adma Biologics (ADMA) Could Rally 28.36%: Here's is How to Trade

The consensus price target hints at a 28.4% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.

Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.

Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates

Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View

Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -10.61% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Adma Biologics (ADMA) Gains But Lags Market: What You Should Know

Adma Biologics (ADMA) closed at $5.26 in the latest trading session, marking a +1.54% move from the prior day.

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $5.18, denoting a +0.58% change from the preceding trading day.

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.